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Lectin/glycosidase competitive assays S20 S4 per well diluted from a stock solution of 10 g·mL -1 in 0.01 M phosphate buffer saline (PBS, pH 7.3 containing 0.1 mM Ca 2+ and 0.1 mM Mn 2+ ) at room temperature. The wells were then washed three times with 300 L of washing buffer (containing 0.05% (v/v) Tween 20; PBST). The washing procedure was repeated after each of the incubations throughout the assay. 
Inhibition (%) = (A(no inhibitor) -A(with inhibitor)) / A(no inhibitor) x 100
Results in triplicate were used for the plotting the inhibition curves for each individual ELLA experiment. Typically, the IC50 values (concentration required for 50% inhibition of the ConAcoating mannan binding) obtained from several independently performed tests were in the range of ±12%. Nevertheless, the relative inhibition values calculated from independent series of data were highly reproducible ( Figure S19A ). NeutrAvidin solution was then transferred into the plates (60 mL/well). After 1 h at 37 °C, these plates were washed twice with Tris (250 L/well) and ABTS was added (50 L/well). Optical density at 415 nm was determined after 5 min. The percent of inhibition was calculated as above indicated for a typical ELLA experiment.
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Synthesis of new compounds
Heptakis[2,3-di-O-methyl-6-(-D-mannopyranosyloxy)hexyl-1H-1,2,3-triazol-4ylmethyl]cyclomaltoheptaose (3).
To a solution containing the 6-azidohexyl derivative 14 1 (0.16 mmol) and the heptapropargylated βCD derivative 15 2 (30 mg, 18.9 mol) in acetone-MeOH Figure S3 . Analytical RP-HPLC spectrum of compound 6. S12 Figure S4 . Analytical RP-HPLC spectrum of compound 8.
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NMR Spectra. 
